Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.06.2017 | review | Ausgabe 2/2017 Open Access

memo - Magazine of European Medical Oncology 2/2017

News in AL Amyloidosis ASH 2016

A rapidly evolving field of investigation

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 2/2017
Autor:
M.D. Hermine Agis

Summary

Amyloidosis is a rare but life-threatening protein misfolding disease. The early diagnosis and enrollment of patients into multicentre trials is of great importance, as is the need for intensive collaboration between multiple medical departments and experienced specialists. In the following review, the most interesting abstracts from the annual American Society of Hematology (ASH) meeting in 2016 are presented. The topics include the limitations of established biomarkers in risk assessment and response evaluation, the introduction of a new biomarker, the comparison of different treatment sequences and the efficacy of a multiple drug regimen in light-chain (AL) amyloidosis.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2017

memo - Magazine of European Medical Oncology 2/2017 Zur Ausgabe